New Meds and Tech from PES Drugs and Therapeutics committee
SKYTROFA®
Anna Ryabets-Lienhard, DO, Christine Yu, MD, Emily Breidbart, MD
In August 2021, FDA approved SKYTROFA® (lonapegsomatropin-tcgd), the first pediatric long-acting growth hormone (GH). Lonapegsomatropin-tcgd is a human growth hormone (GH) that utilizes TransCon® technology allowing once weekly subcutaneous administration of GH. SKYTROFA® is indicated for the treatment of pediatric patients one year and older with GH deficiency and weights of at least 11.5 kg. The recommended subcutaneous dose is 0.24 mg/kg/week administered into the abdomen, buttocks, or thigh with a regular rotation schedule of the injection sites (FDA). It is available as a powder in single-dose, dual-chamber, prefilled cartridges at the doses of 3 mg, 3.6 mg, 4.3 mg, 5.2 mg, 6.3 mg, 7.6 mg, 9.1 mg, 11 mg, and 13.3 mg and delivered via an auto-injector (FDA).
